riociguat
Sign in to saveAlso known as Adempas®, BAY 63-2521, Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate, Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate, Riociguatum
Riociguat, sold under the brand name Adempas, is a medication by Bayer that is a stimulator of soluble guanylyl cyclase (sGC). It is used to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of the class of sGC stimulators. The drug has a half-life of 12 hours and will decrease dyspnea associated with pulmonary arterial hypertension.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 455344444
- Drug.image
- Riociguat_structure.svg
- Drug.image_class
- skin-invert-image
- Drug.alt
- Skeletal formula of riociguat
- Drug.image2
- Riociguat-3D-balls.png
- Drug.image_class2
- bg-transparent
- Drug.alt2
- Ball-and-stick model of riociguat
- Drug.width
- 160
- Drug.tradename
- Adempas
- Drug.DailyMedID
- Riociguat
- Drug.pregnancy_AU
- X
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- C02
- Drug.ATC_suffix
- KX05
- Drug.legal_AU
- S4
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Research
678 papers- Riociguat.2006
- Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.The New England journal of medicine · 2013
- Riociguat for the treatment of pulmonary arterial hypertension.The New England journal of medicine · 2013
- Riociguat.2012
- Riociguat in the Treatment of Pulmonary Arterial Hypertension.Archives of medical research · 2022
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 422.1615
- Has use
- medication
Show 9 more facts
- chemical formula
- C₂₀H₁₉FN₈O₂
- canonical SMILES
- CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC
- World Health Organisation international non-proprietary name
- riociguat
- significant drug interaction
- avanafil
- subject has role
- enzyme activator
- medical condition treated
- pulmonary hypertension
- Commons category
- Riociguat
- defined daily dose
- 4.5
- legal status (medicine)
- boxed warning
Sources (10)
via Wikidata · CC0
~9 min read
Encyclopedic overview
16 sectionsContents
- Contraindications
- Adverse effects
- Interactions
- Chemistry and mechanism of action
- Pharmacology
- History
- Discovery
- Phase I clinical trials
- Phase II clinical trials
- Phase III clinical trials
- CHEST
- PATENT
- Other studies
- Effect of riociguat on bone metabolism
- Interaction study with sildenafil
- References
Riociguat, sold under the brand name Adempas, is a medication by Bayer that is a stimulator of soluble guanylyl cyclase (sGC). It is used to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of the class of sGC stimulators. The drug has a half-life of 12 hours and will decrease dyspnea associated with pulmonary arterial hypertension.
It is available as a generic medication.
Excerpted from Wikipedia’s “riociguat” article, available under the CC BY-SA 4.0 licence.